NICHOL GEOFFREY 4

What Happened
Geoffrey Nichol, a director of Tempest Therapeutics (TPST), was granted an award for 1,230 derivative shares on 2026-01-27. The filing reports an acquisition at $0.00 per share (derivative award), so no cash was exchanged at grant. This was a grant/award rather than a market purchase or sale.

Key Details

• Transaction date: 2026-01-27; reported on Form 4 filed 2026-01-28 (timely filing).
• Transaction type/code: A — Grant, award or other acquisition (derivative).
• Shares granted: 1,230 derivative shares; reported acquisition price $0.00.
• Shares owned after transaction: Not specified in the Form 4 (not disclosed).
• Footnote: The shares underlying the option will vest in full on the earlier of (i) January 27, 2027, or (ii) the day of Tempest’s 2026 annual stockholder meeting, subject to the reporting person’s continuous service through such vesting date.

Context
This is a compensatory equity award (derivative/option-like grant) that vests based on continued service; it is not an open-market purchase or sale and does not involve immediate cash proceeds. Such director grants are common as part of board compensation and should be interpreted as a compensation event rather than a direct market-confidence signal.